REVELATION BIOSCIENCES, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
REVELATION BIOSCIENCES, INC. (REVB) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 9.14 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- REVELATION BIOSCIENCES, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 9.18M shares, a 5960.95% increase year-over-year.
- REVELATION BIOSCIENCES, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 151.50K shares, a 7856.83% increase year-over-year.
- REVELATION BIOSCIENCES, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 1.90K shares.
- REVELATION BIOSCIENCES, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-09-30 was 1.17M shares, a 76.78% increase year-over-year.
- REVELATION BIOSCIENCES, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 4.34M shares, a 5320.42% increase from fiscal 2024.
- REVELATION BIOSCIENCES, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 80.05K shares, a 3204.91% increase from fiscal 2023.
- REVELATION BIOSCIENCES, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 2.42K shares, a 89.00% decline from fiscal 2022.
- REVELATION BIOSCIENCES, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 22.02K shares, a 22.73% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 9.14M shares 10-Q · filed 2026-08-06 | |||||||
| 2026-03-31 | 9.18M shares 10-Q · filed 2026-05-07 | |||||||
| 2025-12-31 | 4.34M shares 10-K · filed 2026-02-26 | |||||||
| 2025-09-30 | 17.36M shares 10-Q · filed 2025-11-06 | |||||||
| 2025-06-30 | 1.69M shares 10-Q · filed 2026-08-06 | 6.72M shares 10-Q · filed 2025-08-08 | ||||||
| 2025-03-31 | 151.50K shares 10-Q · filed 2026-05-07 | 1.69M shares 10-Q · filed 2025-05-08 | ||||||
| 2024-12-31 | 80.05K shares 10-K · filed 2026-02-26 | 960.47K shares 10-K · filed 2025-03-06 | ||||||
| 2024-09-30 | 108.48K shares 10-Q · filed 2025-11-06 | 5.21M shares 10-Q · filed 2024-11-08 | ||||||
| 2024-06-30 | 57.50K shares 10-Q · filed 2025-08-08 | 2.76M shares 10-Q · filed 2024-08-09 | ||||||
| 2024-03-31 | 1.90K shares 10-Q · filed 2025-05-08 | 30.47K shares 10-Q · filed 2024-05-10 | ||||||
| 2023-12-31 | 2.42K shares 10-K · filed 2025-03-06 | 38.96K shares 10-K · filed 2024-03-22 | ||||||
| 2023-09-30 | 1.17M shares 10-Q · filed 2023-11-09 | 5.57K shares 10-Q · filed 2024-11-08 | 166.46K shares 10-Q · filed 2023-11-09 | |||||
| 2023-06-30 | 38.96K shares 10-Q · filed 2024-11-08 | 1.17M shares 10-Q · filed 2023-08-11 | 5.01K shares 10-Q/A · filed 2024-09-23 | 150.50K shares 10-Q · filed 2023-08-11 | ||||
| 2022-12-31 | 22.02K shares 10-K/A · filed 2024-09-23 | 660.96K shares 10-K · filed 2023-03-30 | ||||||
| 2022-09-30 | 661.43K shares 10-Q · filed 2023-11-09 | 661.43K shares 10-Q · filed 2023-11-09 | 23.15M shares 10-Q · filed 2022-11-10 | |||||
| 2022-06-30 | 412.59K shares 10-Q · filed 2023-08-11 | 412.59K shares 10-Q · filed 2023-08-11 | 14.44M shares 10-Q · filed 2022-08-15 | |||||
| 2022-03-31 | 412.59K shares 10-Q · filed 2023-05-22 | 14.44M shares 10-Q · filed 2022-05-16 | ||||||
| 2021-12-31 | 17.95K shares 10-K · filed 2023-03-30 | |||||||
| 2021-09-30 | 4.21M shares 10-Q · filed 2022-11-10 | |||||||
| 2021-06-30 | 4.21M shares 10-Q · filed 2022-08-15 | |||||||
| 2021-03-31 | 4.21M shares 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |